Holen Sie sich die Stockscreener-App
86.95
7.80%
-7.35
Schlusskurs vom Vortag:
$94.30
Offen:
$90.72
24-Stunden-Volumen:
1.65M
Relative Volume:
1.91
Marktkapitalisierung:
$6.26B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-28.05
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
+35.28%
1M Leistung:
+48.22%
6M Leistung:
+84.36%
1J Leistung:
+99.18%
1-Tages-Spanne:
$85.00
$91.10
1-Wochen-Bereich:
$64.26
$103.00
52-Wochen-Spanne:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
86.94 | 6.78B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.25 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.43 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.10 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.38 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.47 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Truist Securities Raises Kymera Therapeutics (KYMR) Price Target - GuruFocus
Oppenheimer Raises Kymera Therapeutics (KYMR) Price Target to $120 | KYMR Stock News - GuruFocus
KYMR: Morgan Stanley Raises Price Target to $127, Maintains Over - GuruFocus
Barclays Raises Kymera Therapeutics (KYMR) Price Target Significantly | KYMR Stock News - GuruFocus
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Kymera Therapeutics slides after launching $500 million share offering - TradingView
Kymera Therapeutics (KYMR): Piper Sandler Raises Price Target to $125 | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down on Insider Selling - MarketBeat
HC Wainwright & Co. Elevates Kymera Therapeutics (KYMR) Price Ta - GuruFocus
Kymera Therapeutics (KYMR) Sees Notable Decline in Stock Price - GuruFocus
Kymera stock price target raised to $125 from $98 at Piper Sandler on positive trial data - Investing.com
Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating - marketscreener.com
Kymera Therapeutics (KYMR) Receives Upgraded Price Target from Leerink Partners | KYMR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating - TipRanks
Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer - TipRanks
Maven Securities LTD Takes $2.18 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Receives Raised Price Target from B o - GuruFocus
Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating - marketscreener.com
Kymera Therapeutics stock price target raised to $116 at Wells Fargo on positive trial data - Investing.com Canada
Oppenheimer raises Kymera Therapeutics stock price target to $120 on promising trial data - Investing.com UK
Kymera Therapeutics CMO Gollob sells $4.37 million in shares By Investing.com - Investing.com South Africa
KYMR: BTIG Raises Price Target and Maintains Buy Rating | KYMR S - GuruFocus
Kymera Therapeutics Insider Sold Shares Worth $8,917,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics stock price target raised to $138 from $75 at BTIG By Investing.com - Investing.com South Africa
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Kymera Therapeutics stock price target raised to $138 from $75 at BTIG - Investing.com Canada
Kymera Therapeutics: Surge in Stock Price - StocksToTrade
Kymera readout hints at new era for degraders in immunology - BioCentury
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 100,000 Shares - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $4,372,051.69 in Stock - MarketBeat
Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CMO Gollob sells $4.37 million in shares - Investing.com
Kymera Therapeutics CEO Nello Mainolfi sells $8.92 million in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Albers sells $448,823 in shares - Investing.com
Kymera Therapeutics CEO Nello Mainolfi sells $8.92 million in shares - Investing.com
Kymera Therapeutics Launches Public Offering of Common Shares - marketscreener.com
Kymera Therapeutics announces $500M proposed public offering - MSN
Raised Price Targets Boost Kymera Therapeutics’ Market Prospects - StocksToTrade
Kymera’s Bold Move: Truly A Game Changer? - timothysykes.com
Kymera Therapeutics stock falls after $500 million share offering By Investing.com - Investing.com India
Kymera Therapeutics (KYMR) Announces $500 Million Stock Offering - GuruFocus
Kymera Therapeutics price target raised to $118 from $70 at Leerink - TipRanks
Kymera Therapeutics stock falls after $500 million share offering - Investing.com
Kymera Therapeutics price target raised to $138 from $75 at BTIG - TipRanks
Kymera Therapeutics launches $500 million public offering - Investing.com
Kymera Therapeutics Announces Proposed Public Offering - The Manila Times
Kymera Therapeutics (NASDAQ: KYMR) plans $500M stock sale plus $75M option - Stock Titan
This drugmaker's stock is soaring over 40% Monday - MSN
This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):